



Earnings Presentation 2Q22

August 12, 2022

Safe Harbor

This presentation may contain considerations referring to the business future prospects, estimates of operational and financial results, the Company's growth outlook, and other future events.

Words, such as, for instance, "anticipate", "believe", "estimate", "expect", "project", "plan", "foresee", "aim", "seek", as well as all variations, and other words of similar meaning, aim at identifying these forward-looking statements. Referred statements involve various factors, risks, or uncertainties, known or unknown, which can result in relevant differences between current data and eventual projections of this presentation and do not represent any guarantee in relation to the Company's future performance.

All the statements herein are based on information and data available on the date these were issued. The Company does not undertake to review them or update them, in any event, if new information arises or due to future events.

Reader/investor is solely responsible for any investment decision, business, or actions taken based on information and statements contained herein. Reader/investor shall not consider only the information contained herein to make decisions concerning the trading of securities issued by the Company. To obtain more detailed information, consult our Financial Statements, the Reference Form, and other relevant information on our investor relations website www.dasa3.com.br.

This presentation neither constitutes a sale offer nor a request of purchase of any security.

2Q22 HIGHLIGHTS



Record revenue of R\$3.5 bn in 2Q22, +24.7% and EBITDA of R\$561.2 mn, with a 17.1% margin



GROWTH REFLECTS SOLID ADVANCES IN BUSINESS EXPANSION AND INTEGRATION

Gross Revenue: R\$3,523 mn, +24.7% vs. 2Q21

Adjusted Gross Profit: R\$975.6 mn, +8.4% vs. 2Q21

Adjusted EBITDA: R\$561.2 mn, with a 17.1% margin

Hospitals & Oncology: +66% gross revenue vs. 2Q21, accounting for 49% consolidated revenue (+12.1 p.p.)

Outpatient Care, Diagnostics and Care Coordination: gross revenue ex-Covid +7.9% vs. 2Q21



DIGITAL INITIATIVES

4.6 mn Nav platform Unique Users: +1.1 mn in 2Q22, +6x vs. 2Q21

29 thousand physicians at **Nav platform:** +3.4 thousand in 2Q22

Telemedicine consultations via Nav: 138 thousand, +26% vs. 2Q21

Web Check-in totaled 495 thousand users in 2Q22, +23x vs. 20 thousand users in 2Q21



ECOSYSTEM GROWTH

The first Integrated Healthcare Center is inaugurated blending the brands *Alta Diagnósticos* and *Nove de Julho*


Inauguration of two new *Alta Diagnósticos* units (Itaim and Alphaville)

Acquisition of CENTRON (RJ) is concluded and acquisition of LUSTOSA (MG) is announced

Solid revenue growth, all-time record in 2Q22

Gross Revenue


R\$ million



Hospitals¹ profitability continues advancing, despite acquired assets under the integration process


Adjusted Gross Profit & Adjusted Gross Margin

R\$ million



Total Beds Installed & Operational Beds


monthly average




¹ BU1: Hospitals & Oncology

Digital platform fast-paced growth with high levels of engagement

Nav
UNIQUE PATIENT USERS (000s)




Nav PRO
UNIQUE PHYSICIAN USERS (000s)



USER RATINGS ON APP

Relevant advance of user satisfaction from June 2021 to June 2022




¹ Based on Grade 1 to 5



Digital initiatives with focus on user experience and efficiency continue gaining traction


Web Check-in (000s)



1 mn check-ins since launch

19% time savings vs. traditional check-in

Nav patients accesses (000s)



Patients using the Nav platform bring a revenue uplift

Telemedicine consultations (000s)

✓ Telemedicine consultations grew 26.0% vs. 2Q21



✓ 138 thousand telemedicine consultations in 6M22

✓ User engagement level remains high

✓ 15 medical specialties available (vs. 9 in 2021)

Ecosystem expansion strategy maximizes value creation and transforms Dasa into Brazil's largest Integrated Healthcare Network

15



HOSPITALS

- ✓ +2x vs. Dec 2020
- ✓ 2nd largest private hospital platform in Brazil
- ✓ Key markets: São Paulo, Rio de Janeiro and Brasília
- ✓ 3,417 total beds

+1,000



PATIENT SERVICE CENTERS

DIAGNOSTICS

- ✓ Latin America's largest diagnostics company
- ✓ + 175 million exams processed in 6M22

35



ONCOLOGY CENTERS

- ✓ +17x vs. Dec 2020
- ✓ 3rd largest independent oncology group in Brazil



- ✓ 34 NTOs including Barueri (largest in Latin America)
- ✓ 1 leading-edge hospital command center

Launch of the Integrated Healthcare Center, combining Alta Diagnósticos and Nove de Julho



Launch of two new Alta Diagnósticos units Strategically located to attract new users and reinforce the brand



Relevant acquisitions support Dasa's positioning as one of Brazil's key private healthcare players

- 8** Assets acquired
- ✓ Strategically located
- ✓ 1,768 beds, in the last 12 months

Hospital	Beds installed	Consolidation
Innova	94	Jan/21
Grupo Carmo	264	Apr/21
Leforte	569	Sep/21
Hospital da Bahia	309	Nov/21
Hospital São Domingos	370	Dec/21
Clinica AMO	-	Jan/22
Hospital Paraná	162	Mar/22
CENTRON	-	May/22

Centron acquisition concluded in May 2022



Lustosa acquisition announced in June 2022



ESG journey advances: public commitments linked to business strategy

PILLARS

- ✓ Social care investments
- ✓ Incentive for diversity
- ✓ Carbon zero goal by 2030
- ✓ Voluntary offset of 100% GHG¹ emissions from hospitals inventoried in 2020

AWARDS & RECOGNITIONS

- ✓ *Guia Diversidade* 2021 (Diversity Guide) – Exame magazine
- ✓ Environmental Awareness Award – Immensità
- ✓ Ethics in Business Award: Diversity & Inclusion, ESG and Social Responsibility



PROJECTS

- ✓ Investment in renewable energies, 17 new solar plants to supply 385 units
- ✓ Medical care for socially vulnerable populations
- ✓ Genomics Surveillance
- ✓ Greenhouse Gas Emissions Inventory

- ✓ Mondó Network
Solutions for vulnerable territories
+400 educators qualified
+100 birth attendants trained



¹ Inventoried Hospitals in 2020

DATA

Hospitals & Oncology

Dasa sustains its place as the 2nd largest independent private hospital network in Brazil

Integration playbook in line with the schedule


Advances vs. 2Q21

- ✓ Net revenue: + 68.9%
- ✓ Total operational beds: +61.1%
- ✓ Occupancy rate: +0.8 p.p., reaching 77.8%
- ✓ Average ticket: +1.7%, to R\$8,311/day
- ✓ Gross margin: in line with 1Q22
- ✓ Hospitals account for 49% of the Company's consolidated revenues (+12.1 p.p.)




Net revenue and hospitals share in consolidated revenue

R\$ million



Adjusted Gross Profit & Adjusted Gross Margin

R\$ million



¹ Second wave of COVID + return of elective procedures

DDSD

Outpatient Care, Diagnostics and Care Coordination

Higher average ticket and higher total number of exams increased revenue by 7.9% ex-Covid


Advances vs. 2Q21

- ✓ Revenue: +7.9%, ex-Covid
- ✓ Average ticket: +6% from R\$534 to R\$567
- ✓ Total number of exams: +6.5%, to 91 thousand
- ✓ Gross margin: -2.2 p.p. vs. 2Q21, ex-readjustment of costs relating to BU2




Net Revenue

R\$ million



Adjusted gross profit & gross margin

R\$ million



Costs and Expenses readjustment




Financial Highlights


Revenue Growth, higher Gross Profit and solid EBITDA

Even compared to 2Q21, quarter benefited from the second wave of Covid and return of elective procedures


Gross Revenue




Adjusted Gross Profit & Adjusted Gross Margin



General and Administrative Expenses



Adjusted EBITDA & Adjusted EBITDA Margin



¹ Includes R\$47 million related to the readjustment of operation costs


Leverage decreases 0.4x vs. 1Q22, besides extension in debt profile

Position as of June 30, 2022


- ✓ **Gross Debt:** R\$9,890 mn
- ✓ **Cash and cash equivalents:** R\$2,561 mn
- ✓ **Net debt:** R\$7,329 mn
- ✓ **Average cost of debt:** CDI + 1.5% p.a.
- ✓ **Debt average term:** 2.7 years

Debt Amortization Schedule

R\$ million



Leverage (Net Debt/LTM EBITDA) (x)¹



¹ Reported LTM EBITDA Proforma includes the calculation of EBITDA generated by acquisitions on an annual basis. English acronym (LTM) for Last Twelve Months.



Thank you

IR Contact

+55 (11) 2630-2097 | ir@dasa.com.br

dasa3.com.br